Cardiometabolic disorders are the linked conditions of abdominal obesity, insulin resistance and type 2 diabetes, high blood pressure, abnormal blood fats and fatty liver. They share causes, tend to occur together, and multiply each other's effect on the risk of heart attack, stroke, heart failure and kidney disease.
A cardiometabolic service treats them as one problem instead of sending you to separate clinics. Cardiologists, endocrinologists, dietitians and sometimes nephrologists and hepatologists agree on one set of targets and one medication plan. Newer diabetes and weight-loss medicines that also protect the heart and kidneys have made this joint approach more important.
Conditions this service looks after
- Metabolic syndrome
- Type 2 diabetes and prediabetes with cardiovascular risk
- Obesity, especially around the waist
- High blood pressure
- Mixed dyslipidaemia: high triglycerides with low HDL cholesterol
- Fatty liver disease linked to metabolic dysfunction (MASLD)
- Chronic kidney disease related to diabetes or blood pressure
- Heart failure with preserved ejection fraction related to obesity
- Polycystic ovary syndrome with metabolic features
- Obstructive sleep apnoea
Tests you may be offered
- Body measurements and blood pressure: Waist circumference, body mass index, and clinic plus 24-hour or home blood pressure.
- Glucose metabolism: Fasting glucose, HbA1c and, where needed, an oral glucose tolerance test.
- Lipid profile with lipoprotein(a): Including non-HDL cholesterol and sometimes ApoB.
- Kidney tests: eGFR and urine albumin to creatinine ratio, an early marker of vessel damage.
- Liver assessment: Liver enzymes, a fibrosis score and ultrasound or elastography.
- Cardiac assessment: ECG, echocardiography, and a coronary calcium score or stress test when indicated.
- Sleep study: If snoring, daytime sleepiness or resistant hypertension suggest sleep apnoea.
Treatments available
- Lifestyle programme: Nutrition, activity, sleep and alcohol, with realistic targets; losing 5 to 10 percent of body weight improves every component.
- SGLT2 inhibitors: Empagliflozin or dapagliflozin lower the risk of heart failure admission and slow kidney disease, with or without diabetes.
- GLP-1 receptor agonists and tirzepatide: Semaglutide and related medicines reduce weight and, in people with established cardiovascular disease, cardiovascular events. They require long-term use and supervision.
- Blood pressure and lipid therapy: ACE inhibitors or ARBs, statins and add-on agents to individual targets.
- Metabolic (bariatric) surgery referral: For severe obesity, where it offers the largest and most durable improvement in diabetes and risk.
- CPAP for sleep apnoea and fatty liver follow-up: Treating associated conditions that feed the cycle.
When to ask for a specialist opinion
- You have three or more of: large waist, raised blood pressure, raised glucose, high triglycerides, low HDL
- You have diabetes and have never had a heart and kidney risk assessment
- Your weight is rising and tablets for pressure, sugar and cholesterol keep being added
- You have fatty liver on a scan
- You have a strong family history of diabetes and early heart disease
Travelling to Türkiye for this care
A visit of 2 to 3 days can deliver the complete assessment and a unified plan from several specialists in one place, which is hard to obtain in fragmented systems. Treatment, though, is years of medication and habit change. Make sure prescriptions such as GLP-1 agonists can be obtained and monitored at home before starting them abroad. Bariatric surgery, if you are considering it, is a separate planned pathway.
Send your reports, scans and a short history and a Clinic-Y coordinator replies within 24 hours with suitable teams and written, all-inclusive proposals side by side. Reviewing your case is free.
الأسئلة المتكررة
Is metabolic syndrome a real disease?
It is a label for a cluster of risk factors that share insulin resistance as a root. The label matters less than treating each component properly.
Are weight-loss injections good for the heart?
In people with obesity and existing cardiovascular disease, semaglutide reduced major cardiac events in a large trial. They are not risk-free, weight often returns on stopping, and they should be prescribed with follow-up.
Can type 2 diabetes go into remission?
Yes, in many people with substantial weight loss, particularly early after diagnosis. It still needs yearly checks, because it can return.